Celecoxib antagonizes the cytotoxic effect of carboplatin in human esophageal cancer cells.
- Author:
Lili SHI
1
;
Desheng ZHONG
;
Chunping GU
;
Le YU
Author Information
- Publication Type:Journal Article
- MeSH: Apoptosis; Blotting, Western; Carboplatin; antagonists & inhibitors; Caspase 3; metabolism; Celecoxib; Cell Line, Tumor; drug effects; Cell Survival; Drug Interactions; Esophageal Neoplasms; metabolism; pathology; Humans; Pyrazoles; pharmacology; Sulfonamides; pharmacology
- From: Journal of Southern Medical University 2014;34(6):792-797
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the antagonizing effect of celecoxib against the cytotoxicity of carboplatin in human esophageal cancer cells.
METHODSThe cell viability of cisplatin-resistant cell line EC109/CDDP and its parental cell line EC109 exposed to carboplatin alone or carboplatin plus celecoxib was determined by MTT assay. The expression of CTR1, caspase-3 activation and PARP cleavage in the exposed cells were examined by Western blotting. Caspase-3 activity and cell apoptosis after the exposure were detected with Caspase-3/7 assay and flow cytometry, respectively. The effect of celecoxib on carboplatin accumulation in the cells was measured using inductively coupled plasma mass spectrometry (ICP-MS).
RESULTSCelecoxib treatment significantly increased the IC50 of carboplatin, suppressed carboplatin-induced caspase-3 and PARP cleavage and caspase-3 activity in EC109 and EC109/CDDP cells. Celecoxib also inhibited carboplatin-induced apoptosis and suppressed intracellular carboplatin accumulation in both cell lines. A combined exposure to celecoxib and carboplatin did not cause significant changes in the protein expression of CTR1.
CONCLUSIONCelecoxib antagonizes the cytotoxic effect of carboplatin and inhibits carboplatin-induced apoptosis in human esophageal cancer cells by reducing intracellular carboplatin accumulation.
